Directorate Change

Oxford Biomedica PLC
01 November 2002


1 November 2002

For further information, please contact:

Oxford BioMedica plc
Professor Alan Kingsman, Chief Executive                Tel: [phone]


Beattie Financial - City/Financial Enquiries
Mike Wort / James Chandler                              Tel: [phone]

Charles Consultants - Scientific/Trade Press Enquiries:
Sue Charles, Katja Stout                                Tel: [phone]



                              OXFORD BIOMEDICA PLC

                           RESIGNATION OF BOARD MEMBER


Oxford, United Kingdom - 1 November 2002.


The Board of Oxford BioMedica plc (LSE:OXB) announces that it has accepted the
resignation of Dr Neill MacKenzie, Executive Director and Senior Vice President
for Business Development, at its board meeting today.

Dr MacKenzie is leaving to pursue his career elsewhere in the biotechnology
industry. The Board thanks him for his significant contribution and wishes him
well for the future.


                                     -Ends-


Notes to Editors

1.   Oxford BioMedica plc
     
     Established in 1995 as a spin out from Oxford University, Oxford BioMedica 
     is an international biotechnology company with a diverse portfolio of 
     products and technology, specialising in gene-based products and technology 
     in the areas of cancer, neurological disease, cardiovascular disease and 
     blood disorders. This is underpinned by over 70 patent families, about 
     quarter of which are issued. Oxford BioMedica plc was floated on the 
     Alternative Investment Market of the London Stock Exchange in December 
     1996, and was promoted to the United Kingdom Listing Authority Official 
     List in April 2001 following a successful £35.5 million fund-raising.

     Oxford BioMedica is headquartered in Oxford, UK and has a wholly-owned
     subsidiary in San Diego, USA

     Currently Oxford BioMedica has corporate collaborations with Aventis, IDM,
     Amersham, Valentis, Virbac and Wyeth. BioMedica has two products in Phase 
     I/II clinical trials: MetXia(R) for late-stage breast cancer, and TroVax(R) 
     for late-stage colorectal cancer.

2.   World Wide Web

     Further information is available on the World Wide Web at http://
     www.oxfordbiomedica.co.uk.



                      This information is provided by RNS
            The company news service from the London Stock Exchange